AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

UCB

Major Shareholding Notification Mar 11, 2025

4017_mrq_2025-03-11_462138b7-9ec5-4059-a2af-d779ec4fd995.pdf

Major Shareholding Notification

Open in Viewer

Opens in native device viewer

Transparency notification BlackRock, Inc.

Brussels (Belgium), 11 March 2025 – 20:00 (CEST)Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from BlackRock, Inc. (having its registered office at 50 Hudson Yards, New York, NY, 10001, U.S.A.), on 7 March 2025.

BlackRock, Inc. notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA decreased and crossed the 5% threshold downwards on 6 March 2025.

On 6 March 2025, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 699 063 UCB shares with voting rights and 215 582 assimilated financial instruments, representing together 5.10% of the total number of shares issued by the company (194 505 658), versus 5.02% (9 906 838 UCB shares and 73 183 assimilated financial instruments) in the previous notification dated 13 November 2024.

2. Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Persons subject to the notification requirement:
Name Address (for legal entities)
BlackRock, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock (Netherlands) B.V. Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited 20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited 12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Asset Management Canada Limited 161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada

BlackRock Asset Management Deutschland AG Lenbachplatz 1 1st Floor, Munich, 80333-MN3, Germany
BlackRock Asset Management North Asia
Limited
15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road,
Central, Hong Kong
BlackRock Financial Management, Inc. 50 Hudson Yards, New York, NY, 10001, U.S.A.
BlackRock Fund Advisors 400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock
Institutional
Trust
Company,
National Association
400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock
Investment
Management
(Australia) Limited
Level 37 Chifley Tower, 2 Chifley Square, Sydney NSW 2000, Australia
BlackRock
Investment
Management
(UK)
Limited
12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC 1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd. 1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217,
Japan
Aperio Group, LLC 3 Harbor Dr Suite 204, Sausalito, CA 94965, U.S.A.
SpiderRock Advisors, LLC Corporation Service Company, 251 Little Falls Drive, Wilmington, DE
19808, U.S.A.
  • Date on which the threshold is crossed: 6 March 2025.
  • Threshold crossed (in %): 5%.
  • Denominator: 194 505 658.

Notified details:

A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to
securities
Not linked to
the securities
Linked to
securities
Not linked to
the
securities
BlackRock, Inc. 0 0 0,00%
BlackRock (Netherlands)
B.V.
3.219 1.337 0,00%
BlackRock (Singapore)
Limited
5.895
10.538
0,01%
BlackRock Advisors (UK)
Limited
1.701.438
1.623.556
0,83%
BlackRock Advisors, LLC 213.637 201.535 0,10%
BlackRock Asset
Management Canada
Limited
131.804 138.714 0,07%
BlackRock Asset
Management Deutschland
AG
176.460 181.285 0,09%
BlackRock Asset
Management North Asia
Limited
3.200 0,00%
BlackRock Financial
Management, Inc.
69.352 73.923 0,04%
BlackRock Fund Advisors 2.556.634 2.445.575 1,26%
BlackRock Institutional
Trust Company, National
Association
1.597.780 1.602.340 0,82%
BlackRock Investment
Management (Australia)
Limited
53.088 51.478 0,03%

UCB News

BlackRock Investment
Management (UK) Limited
2.542.996 2.508.775 1,29%
BlackRock Investment
Management, LLC
574.535
645.042
0,33%
BlackRock Japan Co., Ltd. 231.719 170.111 0,09%
Aperio Group, LLC 45.080 0,02%
Subtotal 9.699.063
9.906.838
4,99%
TOTAL 9.699.063 0 4,99% 0,00%
B) Equivalent
financial
instruments
After the transaction
Holders of equivalent
financial instruments
Type of financial
instrument
Expiration
date
Exercise
period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting
rights
Settlement
BlackRock
Advisors
(UK) Limited
Securities Lent 4.828 0,00% physical
BlackRock
Investment
(UK)
Management
Limited
Securities Lent 196.219 0,10% physical
BlackRock
Investment
Management, LLC
Securities Lent 306 0,00% physical
Financial
BlackRock
Management, Inc.
Contract for Difference 3.685 0,00% cash
BlackRock
Institutional
Trust
National
Company,
Association
Contract for Difference 4.560 0,00% cash
Aperio Group, LLC Depositary Receipt 5.951 0,00%

SpiderRock Advisors,
LLC
Depositary Receipt 33 0,00%
TOTAL 215.582 0,11
%
TOTAL (A & B) #
of
voting
rights
%
of
voting
rights
CALCULATE 9.914.645 5,10%
  • Chain of controlled undertakings through which the holding is effectively held: Please see the full chain of control in the 'Chain of Control' tab.
  • Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc going below 5%

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.

For further information, contact UCB:

Investor Relations Antje Witte T +32 2 559 94 14 [email protected]

Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Talk to a Data Expert

Have a question? We'll get back to you promptly.